Biosimilars: An Emerging Therapeutic Approach

Main Article Content

Mansi Kajale
Sahil Kakuste
Hemant Raut
Amit Kakad
M.R.N Shaikh

Abstract

A biosimilar is an extremely similar version of an existing medication. Biologics' cost, manufacture, administration, and clinical efficacy differ from those of chemically produced medications in certain aspects. Chemical and clinical equivalency to branded, original, low molecular weight chemical pharmaceuticals whose patents have expired defines generic medications. These are offered under a generic name and are practically the same thing as the original product. By 2020, many important biologics are expected to lose their patent protection, giving other biopharmaceutical companies the chance to create comparable biologics. After the first biosimilar was approved in early 2000, the use of biosimilars and similar biologics has expanded in recent years. One of the top producers of comparable biologics is India. In 2012, India created a new regulation for the pre- and post-marketing approval of comparable biologics. The biosimilar’s mode of action mirrors that of its reference drugs and results in very comparable outcomes. Some disorders, including some forms of cancer, can be treated with biologics and their biosimilars. Additionally, numerous medical disorders are treated with biosimilars. Crohn’s disease, arthritis, and ulcerative colitis.

Article Details

How to Cite
Mansi Kajale, Sahil Kakuste, Hemant Raut, Amit Kakad, & M.R.N Shaikh. (2023). Biosimilars: An Emerging Therapeutic Approach. International Journal of Pharmaceutical and Bio Medical Science, 3(09), 495–500. https://doi.org/10.47191/ijpbms/v3-i9-08
Section
Articles

References

I. Meher, Bikash R., et al. "Biosimilars in India; current status and future perspectives." Journal of pharmacy & bioallied sciences 11.1 (2019): 12.

II. https://www.policymed.com/2017/02/2017-biosimilar-update.html

III. https://www.fda.gov/BiologicsBloodVaccines/ResourcesforYou/HealthcareProviders/default.htm

IV. https://www.quebec.ca/en/health/medications/biosimilar-drugs/difference-between-generic-drugs-and-biosimilar-drugs#:~:text=Biosimilar%20drugs%20and%20generic%20drugs,very%20similar%20but%20not%20identical

V. Misra, Monika. "Biosimilars: current perspectives and future implications." Indian journal of pharmacology 44.1 (2012): 12.

VI. Roger SD. Biosimilars: How similar or dissimilar are they? Nephrology. 2006;11:341–6. [PubMed] [Google Scholar]

VII. Schiestl M, Zabransky M, Sörgel F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Des Devel Ther. 2017;11:1509–15. [PMC free article] [PubMed] [Google Scholar]

VIII. Saenger P. Ten years of biosimilar recombinant human growth hormone in Europe. Drug Des Devel Ther. 2017;11:1505–7. [PMC free article] [PubMed] [Google Scholar]

IX. Llano A, Fisher M, McKay G. Biosimilar insulin: the current landscape. Pract Diabetes. 2017;34:51–4. [Google Scholar]

X. Kumar, Rajiv, and Jagjit Singh. "Biosimilar drugs: current status." International Journal of Applied and Basic Medical Research 4.2 (2014): 63.

XI. Agbogbo, Frank K., et al. "Current perspectives on biosimilars." Journal of Industrial Microbiology and Biotechnology 46.9-10 (2019): 1297-1311.

XII. Padda, Inderbir S., et al. "Biosimilars use in medicine for inflammatory diseases." (2021).

XIII. Shivani P. Reddy and Catherine Ni and Jashin J. Wu. ''Chapter 14 – Biosimilars'' Elsevier. https://doi.org/10.1016/B978-0-323-44797-3.00014-1 https://www.sciencedirect.com/science/article/abs/pii/B9780323447973000141

XIV. Kang, Hye-Na, et al. "The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019." Biologicals 65 (2020): 1-9.

XV. https://ibkp.dbtindia.gov.in/DBT_Content_Test/CMS/Guidelines/20181115140059519_Guidelines-on-Similar-Biologics-2016.pdf

XVI. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars

XVII. https://www.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/biosimilars

XVIII. https://www.cancer.org/cancer/managing-cancer/treatment-types/biosimilar-drugs.html

XIX. Calvo, Begoña, and Leyre Zúñiga. "Risk management plan and pharmacovigilance system. Biopharmaceuticals: biosimilars." Risk management trends. IntechOpen, 2011.